To identify actionable molecular regulators and potential therapeutic targets of malignant retinoblastoma progression, emphasizing the significance of these targets in treatment.
Key Findings:
Identified 10 retinal cell types, including two MKI67⁺ proliferative RB subpopulations, with implications for targeted therapy.
BIRC5 was overexpressed in 93.7% of MKI67⁺ cells, promoting proliferation and invasion, highlighting its role in aggressive retinoblastoma.
BIRC5 knockdown induced G1 cell cycle arrest and increased apoptotic activity, suggesting a potential therapeutic strategy.
Interpretation:
BIRC5 acts as a cell-state-specific regulator of malignant proliferation in retinoblastoma, indicating its strong potential as a therapeutic target.
Limitations:
Study focused on a limited number of retinoblastoma tumors and normal samples, which may affect the generalizability of the findings.
Further validation in clinical settings is required to confirm the therapeutic potential of targeting BIRC5.
Conclusion:
BIRC5 represents a promising molecular target for therapy in highly proliferative retinoblastoma subpopulations.
